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Circulation: Cardiovascular Quality and Outcomes

ORIGINAL ARTICLE

Determinants of Value in Coronary Artery
Bypass Grafting

BACKGROUND: Over 180 000 coronary artery bypass grafting (CABG)
procedures are performed annually, accounting for $7 to $10 billion in episode
expenditures. Assessing tradeoffs between spending and quality contributing
to value during 90-day episodes has not been conducted but is essential
for success in bundled reimbursement models. We, therefore, identified
determinants of variability in hospital 90-day episode value for CABG.
METHODS: Medicare and private payor admissions for isolated CABG
from 2014 to 2016 were retrospectively linked to clinical registry data for
33 nonfederal hospitals in Michigan. Hospital composite risk-adjusted
complication rates (≥1 National Quality Forum-endorsed, Society of
Thoracic Surgeons measure: deep sternal wound infection, renal failure,
prolonged ventilation >24 hours, stroke, re-exploration, and operative
mortality) and 90-day risk-adjusted, price-standardized episode payments
were used to categorize hospitals by value by defining the intersection
between complications and spending.
RESULTS: Among 2573 total patients, those at low- versus high-value
hospitals had a higher percentage of prolonged length of stay >14 days
(9.3% versus 2.4%, P=0.006), prolonged ventilation (17.6% versus 4.8%,
P<0.001), and operative mortality (4.8% versus 0.6%, P=0.001). Mean
total episode payments were $51 509 at low-compared with $45 526
at high-value hospitals (P<0.001), driven by higher readmission ($3675
versus $2177, P=0.005), professional ($7462 versus $6090, P<0.001),
postacute care ($7315 versus $5947, P=0.031), and index hospitalization
payments ($33 474 versus $30 800, P<0.001). Among patients not
experiencing a complication or 30-day readmission (1923/2573, 74.7%),
low-value hospitals had higher inpatient evaluation and management
payments ($1405 versus $752, P<0.001) and higher utilization of
inpatient rehabilitation (7% versus 2%, P<0.001), but lower utilization
of home health (66% versus 73%, P=0.016) and emergency department
services (13% versus 17%, P=0.034).
CONCLUSIONS: To succeed in emerging bundled reimbursement
programs for CABG, hospitals and physicians should identify strategies
to minimize complications while optimizing inpatient evaluation and
management spending and use of inpatient rehabilitation, home health,
and emergency department services.
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WHAT IS KNOWN
• Extensive variation in the quality of coronary artery
bypass grafting care has prompted the establishment of quality measures through the Society of
Thoracic Surgeons and National Quality Forum.
• Sources of variation in 90-day episode payments
for isolated coronary artery bypass grafting
include readmission, professional, and postacute
care payments.

WHAT THE STUDY ADDS
• This study adds specific targets for succeeding in
bundled care reimbursement models by incorporating both risk-adjusted clinical outcomes and
risk-adjusted, price-standardized 90-day episode
payments to assess value (ie, quality/spending).
• High-value hospitals’ performance in Michigan
was driven by avoiding prolonged length of stay,
prolonged intubation, and operative mortality, in
conjunction with achieving lower episode spending in all areas.
• Patients who avoided complications or readmissions at high-value hospitals had lower inpatient
evaluation and management spending and lower
utilization of inpatient rehabilitation, but higher
utilization of home health and emergency department services.

A

pproximately 300 000 adults undergo cardiac
surgery annually, and over half include coronary
artery bypass grafting (CABG), accounting for
≈$7 to 10 billion in episode expenditures.1–3 As a result,
CABG is one of the most widely studied inpatient surgical procedures and has become a target for bundled
payment models. Extensive work has been performed
describing hospital variation in the quality of CABG
care,4–9 prompting the establishment of quality measures through the Society of Thoracic Surgeons (STS)
and National Quality Forum.10 Despite these efforts, less
attention has been paid to the relationship between
quality and spending.
The Bundled Payments for Care ImprovementAdvanced (BPCI-A) program was initiated on October
1, 2018 by the Center for Medicare & Medicaid Services
to implement voluntary episode payment models11 and
hold providers accountable for the quality and expenditures throughout an episode of care. A number of
investigators have identified hospital variation in clinical outcomes after CABG, including mortality,4,12 complications,5–7,12 and failure to rescue,4,8,9,12 but have not
assessed spending. Other investigators have reported
wide hospital variation in episode payments after cardiac surgery but have not assessed clinical outcomes.3,13
While health care reform efforts such as the BPCI have
focused on optimizing value (defined as quality divided

by expenditures), few studies have examined the relationship between clinical outcomes and episode payments to identify how high-value hospitals achieve
their performance, whether through increasing quality, decreasing payments, or both. The few studies that
have characterized value in performing CABG have
either been performed at a single center,14 limited to
one outcome (pneumonia),2 or used hospital costs and
charge-to-cost ratios, which may not accurately reflect
real-world spending.14–16 In contrast, an analysis linking
established measures of clinical outcomes (eg, complications and mortality) with episode payments could
help hospitals identify targets to increase value and succeed in the BPCI or other similar programs.
To help hospitals, payors, and providers better navigate value-based reimbursement models, clinical outcomes data were linked to 90-day episode payments
housed within 2 statewide quality improvement collaboratives. These data were used to assess determinants
of high-value episodes for CABG surgery.

METHODS
The University of Michigan Institutional Review Board deemed
this study to be exempt from review. These data cannot be
made available due to data use restrictions. Additional details
pertaining to analytic methods are available from the corresponding author upon reasonable request.

Data Sources
Episode payments were collected from the Michigan Value
Collaborative (MVC), a group of 87 Michigan acute care hospitals and 31 physician organizations that seeks to achieve
the best possible patient outcomes at the lowest reasonable
cost. The MVC Coordinating Center uses Medicare fee-forservice claims data and Blue Cross Blue Shield of Michigan
preferred provider organization claims to create a validated
registry of comprehensive 90-day episodes of care among
Michigan patients.17
Clinical data were collected through the Michigan
Society of Thoracic and Cardiovascular Surgeons Quality
Collaborative (MSTCVS-QC), developed in 2001 as a cardiac
surgeon-led quality collaborative embedded in the MSTCVS.
In 2005, the MSTCVS-QC became partially funded by the
Blue Cross/Blue Shield of Michigan insurance company. The
collaborative meets quarterly to review hospital-specific
processes and outcomes, and to facilitate and evaluate
quality improvement studies to improve the outcomes of
cardiac and general thoracic surgical patients in Michigan.
The MSTCVS-QC gathers data from all 33 nonfederal hospitals in Michigan that provide cardiac surgery. On a quarterly
basis, each of the 33 nonfederal adult cardiac surgical hospitals in Michigan send the MSTCVS-QC data coordinating
center a copy of their STS national harvest file through a
certified STS vendor.
Hospital characteristics were collected through the
American Hospital Association Annual Survey and included
the following reported variables: number of beds, teaching
status, and urban designation.
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Patient Population
Isolated CABG 90-day episodes were identified within the
MVC based on admission date ranges (June 1, 2014 through
June 1, 2016) for Blue Cross Blue Shield of Michigan and
Medicare beneficiaries residing in Michigan (n=2782).
Procedures from both data warehouses were successfully
probabilistically matched (match rate 92.5%, n=2573) using
an algorithm that included hospital, surgeon, patient date of
birth, gender, admit date, and discharge date (Appendix in
the Data Supplement).

Defining Hospital Value
A centered mean complication rate and centered mean total
episode payment was defined empirically for each of the
33 hospitals. For clinical risk-adjustment, observed/expected
ratios were created by dividing the patient-level observed
complication rate by the expected morbidity and operative
mortality according to the National Quality Forum-endorsed
STS CABG composite measure risk-adjustment model.10 The
observed/expected ratio for each hospital was then multiplied
by the crude complication rate to form a risk-adjusted mean
complication rate. Each hospital was added to a scatter plot
of risk-adjusted centered means, with each dot representing
one hospital and weighted in size by its overall isolated CABG
volume (Figure 1). Hospitals were subsequently defined as
low or high value based on their risk-adjusted complication
rates and spending as compared with the centered means.
While analyses were primarily focused on the comparison
between low- versus high-value hospitals (Tables 1 through
3), a more complete analysis of all hospital value strata was
also conducted (Tables I and II in the Data Supplement).
To distinguish between the quality and spending determinants of hospital value, a subset analysis was additionally
performed among patients who did not experience a complication or 30-day readmission (n=1923/2573, 74.7%). This
analysis focused on identifying differences in episode payments between low- and high-value hospitals for uncomplicated isolated CABG.

Clinical Data
All processes of care and clinical outcomes measures were
selected based on their inclusion in either the STS CABG
performance measures10 or as part of the Merit-Based
Incentive Payment System under Center for Medicare &
Medicaid Services.18
Processes of care measures included preoperative β
blocker, appropriate antibiotic selection and discontinuation,
use of internal mammary artery, and aspirin, β blockers, and
lipid-lowering statins at discharge. In accordance with the STS
and the National Quality Forum,10 the composite postoperative outcomes measure included any of the following: deep
sternal wound infection, renal failure, prolonged ventilation
(>24 hours), stroke, surgical re-exploration, and operative
mortality. Prolonged length of stay was defined as >14 days.
Operative mortality was defined as death during hospitalization in which CABG was performed or within 30 days after
surgery. Risk-adjusted 30-day readmission was derived from
an STS model of Medicare fee-for-service beneficiaries only10
and thus could not be included in the composite complication

rate observed/expected ratio calculation. Instead, a regression
of unadjusted 30-day readmission with morbidity and operative mortality was conducted to determine a risk-adjusted
readmission rate. The distribution of hospitals by centered
mean readmission rate and 90-day episode payments is displayed in Figure I in the Data Supplement.

Ninety-Day Price-Standardized Episode
Payments
The primary outcome was total 90-day price-standardized
episode payments. Payments were quantified for 90-day
episodes of care and were disaggregated into index hospitalization, professional, readmission, and postacute care
components and further subcomponents.19 Patient clinical
demographic data for these episodes were collected using
International Classification of Diseases-Ninth Revision codes.
Payments were price-standardized using average Medicare
payments in the state of Michigan to account for payer-type,
inflation, regional variation, and contractual differences.20
Price standardization ensures that variation in payments
reflects differences in health care utilization rather than differences in geographic reimbursement.
Readmission and postacute care payments were reported
as mean component payments and as conditional on use,
which restricted payments to patients who were readmitted,
received postacute care, or both. Postdischarge payments
were restricted to patients known to be alive at hospital discharge (low-value hospitals: 568/587, 96.8% and high-value
hospitals: 1023/1027, 99.6%).

Statistical Analyses
Total and component payments were risk-adjusted using a
2-step regression model, adjusting for patient characteristics,
comorbidities, and payments in the 6 months before the index
procedure. Risk adjustment was performed using observed/
expected ratios as previously described.13 Among component
and subcomponent payments, percent attributed to the total
difference in payments between groups was reported. Since
total and component episode payments were risk-adjusted
separately, component percentages attributed to the total
difference may not equal 100%. A sensitivity analysis was
performed to compare mean inpatient evaluation and management (E&M) payments indexed per hospital day between
low- versus high-value hospitals in both the primary and
subset analyses to evaluate differences not attributed to the
number of days spent in the hospital. Hospital days used to
index these payments consisted of the total length of stay
during the 90-day episode, including any readmissions.
A Pearson weighted product-moment correlation coefficient was calculated for Figure 1 and Figure I in the Data
Supplement to incorporate hospital procedural volume.
Categorical variables were presented as percentages, continuous variables as mean (SD), and payments as mean (SE).
Mann-Whitney U or Kruskal-Wallis tests were used to test
continuous hospital-level variables and aggregated patientlevel characteristics among low- versus high-value and all 4
hospital categories, respectively. χ2 tests were used for hospital-level variables. Payment data were tested using a generalized estimating equation treating hospital as a cluster unit.
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Figure 1. Deviation from centered mean in complication rate (x axis) and total episode payments (y axis).
Plotted dots are weighted by hospital volume of isolated coronary artery bypass grafting procedures. Quadrants are labeled as high or low spending and complication rates. Complications included any of the following: deep sternal wound infection, renal failure, prolonged ventilation (>24 h), stroke, surgical re-exploration,
and operative mortality. Centers in the high spending and high complication rate quadrant are considered low-value, while those in the low spending and low
complication rate quadrant are considered high-value. Pearson-weighted correlation coefficient=0.51.

P values of <0.05 (2-tailed) were considered statistically
significant. All analyses were conducted using SAS 9.4 (SAS
Institute, Cary, NC).

RESULTS
Hospital Value Distribution
Eight hospitals (n=587) had high spending and a high
complication rate (low-value hospitals), 15 hospitals
(n=1027) had low spending and a low complication rate
(high-value hospitals), 3 hospitals (n=448) had low spending and a high complication rate, and 7 hospitals (n=511)
had high spending and a low complication rate (Figure 1).

Hospital Structure and Processes
The distribution of Medicare patients, hospital structural characteristics, and compliance with performance processes did not differ between high- and
low-value hospitals (Table 1). Patients in low-value
hospitals had a higher mean number of hierarchical condition categories (5.7 [1.2] versus 4.6 [0.6],
P=0.012), longer mean intensive care unit length of
stay (123 [78] versus 63 [20] hours, P=0.008) and
overall postoperative length of stay (8.9 [2.8] versus 6.4 [0.8] days, P=0.002), and a higher rate of
unplanned readmission within 30 days (20.6% versus
13.4%, P=0.005).
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Table 1.

Hospital Characteristics Stratified by Low-Value and High-Value Hospitals Defined by Spending and Complication Rate Category

Overall
Hospitals, n
Total patients, n
Percent medicare CABG patients, mean % per hospital

High spending and high
complication rate
(low-value)

Low spending and low
complication rate
(high-value)

P value

33

8

15

2573

587

1027

77

76

78

0.52

Hospital structure
 Mean beds, n (SD)

464 (241)

460 (266)

411 (219)

0.52

 Teaching, %

97

88

100

0.36

 Urban, %

90

100

86

0.52

 Compliance with all processes

93.5

93.3

93.9

0.70

 Aspirin at discharge

99.2

99.9

98.8

0.21

 β-blockers at discharge

99.6

99.9

99.4

0.21

 Lipid-lowering statin at discharge

98.7

99.6

98.6

0.24

 Preoperative β-blockers

97.3

95.8

97.8

0.42

 Use of internal mammary artery

99.1

99.5

99.4

0.62

 Appropriate antibiotic selection

99.9

100

100

1.00

 Appropriate antibiotic discontinuation

99.5

99.5

99.4

0.50

Hospital processes, % compliance

Clinical characteristics
 Mean HCCs, n (SD)

4.9 (0.9)

5.7 (1.2)

4.6 (0.6)

0.012

 Mean admission to discharge LOS, d (SD)

9.6 (2.1)

11.6 (3.4)

8.6 (0.9)

0.006

  Mean surgery to discharge LOS, d (SD)

7.2 (1.8)

8.9 (2.8)

6.4 (0.8)

0.002

  Mean ICU LOS, h (SD)

80 (49)

123 (78)

63 (20)

0.008

 Emergency department visit, %

19.3

16.9

18.8

0.35

 Unplanned readmission rate, %

17.2

20.6

13.4

0.005

 Overall complication rate, %

11.1

20.8

6.7

<0.001

 Elective

50.0

45.3

54.3

0.11

 Emergent

1.7

2.0

1.8

0.57

 Emergent salvage

0.2

0.9

0.0

0.13

 Urgent

48.1

51.9

43.9

0.19

Surgery status, %

CABG indicates coronary artery bypass grafting; HCC, hierarchical condition category; ICU, intensive care unit; and LOS, length of stay.

Risk-Adjusted Clinical Outcomes
Risk-adjusted rates of prolonged hospital length of stay
(low-value: 9.3% versus high-value: 2.4%, P=0.006),
prolonged ventilation (low-value: 17.6% versus highvalue: 4.8%, P<0.001), and operative mortality (lowvalue: 4.8% versus high-value: 0.6%, P<0.001) were
higher at low- compared with high-value hospitals,
while adjusted rates of deep sternal wound infection,
renal failure, stroke, surgical re-exploration, and 30-day
readmission did not statistically differ (Table 2).

Ninety-Day Price-Standardized Episode
Payments
Mean total episode payments were higher at low-value hospitals ($51 509 [$1024] versus $45 526 [$402],

P<0.001). Nearly half (45%, $2674) of the difference
in spending between low- and high-value hospitals
was accounted for by higher index hospitalization
spending (Figure 2).
Eighty-one percent of the difference in professional
payments at low- and high-value hospitals were driven
by inpatient E&M payments (low: $2109 [$96] versus
high: $1004 [$35], P<0.001). Inpatient E&M payments
remained higher at low- compared with high-value hospitals when indexed by hospital days ($183 [$5] versus
$108 [$4] per hospital day, P=0.002). Sixty-eight percent of the difference in postacute care payments was
driven by inpatient rehabilitation payments (low: $1419
[$230] versus $489 [$94], P=0.005). A higher proportion of patients at low-value hospitals were readmitted
(20% versus 15%, P=0.006) and used postdischarge
inpatient rehabilitation (10% versus 4%, P<0.001),
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Table 2. Risk-Adjusted Composite and Individual Outcomes Stratified by Low-Value (High Spending and High Complication
Rate) and High-Value (Low Spending and Low Complication Rate) Hospitals
Overall
Hospitals, n

Low-value

High-value

P value

33

8

15

Total patients, n

2573

587

1027

Risk-adjusted composite major morbidity
and mortality, %

11.0

21.0

6.6

<0.001

 Prolonged length of hospital stay (>14 d)

4.4

9.3

2.4

0.006

 Deep sternal wound infection

0.2

0.1

0.2

0.63

 Postoperative renal failure

1.5

2.2

1.0

0.16

 Prolonged intubation/ventilation

8.5

17.6

4.8

<0.001

 Stroke/cerebrovascular accident

1.3

1.1

1.7

0.88

 Operative mortality

1.8

4.8

0.6

<0.001

 Surgical re-exploration

2.5

4.5

1.3

0.26

30-day risk-adjusted readmission rate

11.3

11.7

10.8

0.25

while a smaller proportion used home health (66% versus 74%, P=0.001) and emergency department services
(15% versus 19%, P=0.024). Patients in the low complications/high spending hospital group had similar mean
inpatient E&M payments ($1727 [$79]) as low-value
hospitals ($2109 [$96]) but had a similar proportion of
patients using emergency department services (20%) as
high-value hospitals (19%; Table III in the Data Supplement). Among patients with any payments, overall postacute care payments were higher at low-value hospitals
($7908 [$576] versus $6247 [$223], P=0.013; Table 3).

Payment Variation Among Patients
Without Complications
Among patients who did not experience a complication
or readmission (n=1923/2573, 74.7%), total episode
payments no longer statistically differed between lowvalue versus high-value hospitals ($42 489 [$552] versus
$41 380 [$325], P=0.11). Low-value hospitals had higher professional payments ($6160 [$88] versus $5596
[$57], P<0.001), especially higher inpatient E&M payments ($1405 versus $752, P<0.001), which remained
higher at low- compared with high-value hospitals when
indexed by hospital days ($171 [$6] versus $95 [$4] per
hospital day, P=0.002). In contrast, index hospitalization
and postacute care payments were not statistically different between low- and high-value hospitals. In addition, a
higher proportion of patients at low-value hospitals used
inpatient rehabilitation (7% versus 2%, P<0.001), while
a smaller proportion used home health (66% versus
73%, P=0.016) and the emergency department (13%
versus 17%, P=0.034; Table IV in the Data Supplement).

DISCUSSION
In this large, multi-center, statewide experience, variability existed both in health care quality and spending

across hospitals in a 90-day episode following isolated CABG. Specifically, low-value hospitals had higher
rates of prolonged hospital stay (9.3% versus 2.4%),
more patients with prolonged ventilation (17.6% versus 4.8%), and a higher operative mortality (4.8%
versus 0.6%). Additionally, low-value hospitals had
higher total and component 90-day episode payments.
Patients not experiencing a complication or rehospitalization at low- compared with high-value hospitals had
higher professional payments and a higher rate of inpatient rehabilitation utilization, but lower rates of home
health and emergency department utilization.
This study has several limitations. First, while representing the predominant health care payors in Michigan
(Medicare, Blue Cross Blue Shield of Michigan), the MVC
does not capture other important payors (eg, Medicaid)
and the distribution of payors may differ by hospital. Second, although the present study represents the experience of all 33 nonfederal hospitals performing cardiac
surgery in Michigan, these findings may not be generalizable outside of Michigan or to procedures other than isolated CABG. Third, while the results from this study were
risk-adjusted and price-standardized, all important confounding factors may not be accounted for. Last, while
the MVC collects the majority of expenses reimbursed
during a 90-day episode, not all relevant expenditures
may be captured from both a payor (eg, pharmaceutical)
and patient (eg, out of pocket expenses) standpoint.
These data indicate that high-value hospitals succeeded in part by minimizing complications, but also
had lower professional services spending and differences in component postacute care utilization among
patients without postoperative complications or readmissions. Hospitals engaged in bundled care models
may succeed by investing in home health and emergency department services in efforts to avoid readmissions
and inpatient rehabilitation. Although not statistically
significant (P=0.19), low-value hospitals had a higher
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Figure 2. Variation in total and component 90-day episode payments after coronary artery bypass grafting in low- and high-value hospitals among
the overall population (n=2573) and only patients who did not experience a complication or get readmitted within 30 days (n=1923).
Complications included any of the following: deep sternal wound infection, renal failure, prolonged ventilation (>24 h), stroke, surgical re-exploration, and operative mortality. Postacute care payments include inpatient and outpatient rehabilitation, home health, skilled nursing facility, emergency department, and other
outpatient facility payments.

proportion of nonelective operations. While this difference may reflect differences in disease severity, clinical
risk-adjustment was performed, and it may alternatively indicate better patient selection and preoperative optimization at high-value hospitals. Succeeding in
preoperative preparation and appropriate patient selection may not only result in decreased rates of prolonged
hospital stay, prolonged ventilation, and operative
mortality, but could also decrease spending for inpatient E&M through fewer postoperative consultations.
Additionally, low-value hospitals may have higher E&M
payments due likely in part to poor care coordination21
or evaluating patients on a more frequent basis, as has
been reported with increased laboratory testing at lowcompared with high-ranked medical centers.22
Prior investigators have evaluated value for cardiac
surgical patients. The Virginia Cardiac Services Quality
Initiative leveraged clinical data along with risk-adjusted
cost-to-charge ratios to identify targets for advancing
value. The authors reported a strong positive correlation between risk-adjusted quality (eg, morbidity and
mortality) and risk-adjusted length of stay, but not
between risk-adjusted quality and cost measures.15

Similarly, the current study found a higher incidence
of prolonged length of stay at low-value hospitals and
a mean 2.5-day longer length of stay compared with
high-value hospitals. In contrast to the Virginia Cardiac
Services Quality Initiative analysis, the current study
includes specific National Quality Forum-defined quality
metrics included as part of STS national CABG hospital
performance ratings. Additionally, the Virginia Cardiac
Services Quality Initiative authors did not find a significant association between quality and cost, potentially
because they reported cost-to-charge ratios rather than
spending. Authors of another recent study used a proprietary accounting tool in conjunction with 10 clinical
outcome metrics used to define perfect care.14 Similar
to the current study, the authors used STS performance
metrics, as well as additional metrics deemed more
closely tied to cost. However, the analysis was limited
to a single center, with uncertain application at other hospitals, whereas the current data were collected
from 33 diverse hospitals and as episode payments are
more generalizable in assessing reimbursement. In further contrast to the current analysis and similar to the
Virginia Cardiac Services Quality Initiative analysis,15 the
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Table 3. Mean (SE) Risk-Adjusted, Price-Standardized 90-Day Total and Component Episode Payments in Low-Value (High Spending and High
Complication Rate) and High-Value (Low Spending and Low Complication Rate) Hospitals
Overall
Hospitals, n
Total patients, n
Patients, mean n (SD) per hospital

Low-value

High-value

33

8

15

2573

587

1027

P value

78 (51)

73 (59)

68 (38)

0.85

Total payments, $

48 099 (375)

51 509 (1024)

45 526 (402)

<0.001

Index hospitalization, $

31 928 (186)

33 474 (546)

30 800 (213)

<0.001

Professional services, $

6511 (56)

7462 (157)

6090 (67)

<0.001

 Surgical procedures

3244 (22)

3273 (50)

3195 (30)

0.25

 Inpatient E&M services

1372 (33)

2109 (96)

1004 (35)

<0.001

248 (4)

286 (8)

238 (5)

0.010

 Outpatient E&M services
 E&M consult (inpatient and outpatient)

115 (7)

161 (18)

107 (11)

0.027

 Anesthesia

925 (7)

980 (15)

935 (11)

0.43

 Imaging

274 (4)

330 (10)

269 (6)

0.038

 Labs and tests

93 (3)

118 (7)

86 (5)

0.017

 Other professional

231 (14)

266 (32)

181 (17)

0.003

Overall readmission, $

3115 (213)

3675 (485)

2177 (246)

0.005

 n patients with any $

471 [19%]*

116 [20%]*

149 [15%]*

0.006

23 746 (1285)

25 955 (2671)

20 939 (1763)

0.07

Overall postacute care, $

6614 (194)

7315 (539)

5947 (216)

0.031

 n patients with any $

2457 [97%]*

546 [93%]*

983 [96%]*

0.020

6964 (202)

7908 (576)

6247 (223)

0.013

 Inpatient rehabilitation

927 (97)

1419 (230)

489 (94)

0.005

  n patients with any $

163 [6%]*

61 [10%]*

40 [4%]*

<0.001

 $, when present

 $, when present

29 109 (2093)

28 874 (2929)

24 982 (2900)

0.65

 Outpatient rehabilitation

  $, when present

489 (19)

466 (31)

496 (26)

0.67

  n patients with any $

1396 [55%]*

300 [51%]*

571 [56%]*

0.08

938 (33)

847 (49)

929 (41)

0.86

  $, when present
 Skilled nursing facility

1585 (115)

1862 (278)

1668 (184)

0.58

  n patients with any $

433 [17%]*

113 [19%]*

181 [18%]*

0.42

  $, when present

16 860 (974)

22 666 (2132)

16 939 (1485)

0.88

2373 (40)

2100 (97)

2368 (65)

0.25

1947 [77%]*

386 [66%]*

755 [74%]*

0.001

  $, when present

3199 (41)

3258 (114)

3286 (66)

0.89

 Facility emergency department

316 (20)

205 (28)

276 (24)

0.021

510 [20%]*

88 [15%]*

200 [19%]*

0.024

1788 (85)

1537 (151)

1590 (92)

0.77

 Home health
  n patients with any $

  n patients with any $
  $, when present
 Other outpatient facility

698 (48)

834 (144)

706 (71)

0.33

  n patients with any $

2007 [79%]*

383 [65%]*

855 [83%]*

<0.001

912 (62)

1302 (222)

864 (86)

0.033

  $, when present

Conditional-on-use payments only include patients alive at discharge (overall: 2542/2573, 98.8%; low-value: 568/587, 96.8%; high-value: 1023/1027, 99.6%)
who used readmission payments, postacute care payments, or both. E&M indicates evaluation and management.
* Percentages in brackets were calculated by number of patients using each post-discharge category divided by the number of patients alive at discharge in
each column.

authors quantified actual costs to the hospital.14 While
cost-to-charge ratios and other measures of hospital
cost are informative for hospital operations, incorporating spending by payors is essential to be competitive
in value-based bundled reimbursement models, since

measures from the BPCI-A and similar models are based
on payments received.
Avedis Donabedian defined a hospital’s performance
as the byproduct of processes of care, outcomes, and a
hospital’s structure.23 Since metrics of process and struc-
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ture are conceptually important,23 but largely unmeasured,7 most prior assessments of hospital performance
have consisted of measuring variation in outcomes,5,7,8
finances (eg, charges, hospital costs, payments),3,13,24
or both (eg, value).2,14–16,25 In this study, existing metrics
reflecting both hospital structure (from the American
Heart Association survey) and processes of care (from
the STS) were largely similar across categories of hospital value (Table 1), but may inadequately capture these
aspects of quality. Important differences were identified
in outcomes, with higher rates of prolonged hospital stay,
prolonged intubation, and operative mortality at low-value hospitals. In the context of bundled payment models,
traditional conceptual models for assessing institutional
quality should be broadened to capture the application of
learning health system principles to quality improvement
cycles in routine practice.26–28 While Donabedian provides
a commonly cited framework for quality, efforts focusing on value will require modifications to Donabedian’s
model to include spending. Accordingly, the current study
also included analyses of risk-adjusted, price-standardized
episode payments rather than hospital charges, cost-tocharge ratios, or other estimates of cost.15,16,24 Episode
payments are a better reflection of payers’ and society’s
perspective on cost, since they reflect the actual realized
cost of the episode of care and are thus more relevant to
bundled payments and value-based reimbursement.
Given the importance of spending, one prior analysis of
MVC data assessed reimbursement by evaluating variation
in episode payments after isolated CABG.3 Sources of variation between the highest and lowest hospital payment
quartiles were readmission (35.1% higher), professional
(33.9% higher), and postacute care (29.6%) payments.
Subcomponent drivers of payment differences included
diagnosis related group distribution, inpatient E&M services, higher utilization of inpatient rehabilitation, and
patients with multiple readmissions.3 Similarly, the current study identified inpatient E&M professional payments
and postdischarge inpatient rehabilitation payments to be
the main drivers of payment variation between hospitals.
Importantly, inpatient E&M payments are driven by the
duration of a patient’s hospital stay, while inpatient rehabilitation payments are driven by utilization (yes versus
no), since the latter’s payments are based on diagnosisrelated group pricing rather than care intensity. However,
when indexed by hospital day, inpatient E&M payments
were still higher at low-value hospitals both overall and
among patients avoiding complications or readmission.
These findings may suggest that high-value hospitals are
more protocoled in standard care resulting in lower inpatient E&M payments, independent of time spent in the
hospital. The present analysis further advances these prior
findings by incorporating risk-adjusted clinical outcomes
to evaluate value and defining specific targets for succeeding in bundled care reimbursement models, especially
among patients without complication or readmission.

After initially introducing mandatory bundled payment models in 2016, Center for Medicare & Medicaid
Services announced the voluntary BPCI-A model and
enrolled its first cohort in October of 2018.11 Michigan quality improvement collaboratives are uniquely
situated to evaluate the BPCI-A in future analyses by
linking MSTCVS-QC risk-adjusted clinical data to MVC
90-day episode payments to compare the performance
of BPCI-A participants to nonparticipants. While Michigan includes a diverse set of geographies and practice
environments to analyze, a similar nationwide analysis
of Medicare patients could be performed by linking
STS clinical data to Medicare claims. These future data
could further highlight specific strategies for success in
BPCI-A and other value-based payment models.

CONCLUSIONS
In conclusion, high-value hospitals’ performance was
driven by avoiding prolonged length of stay, prolonged
intubation, and operative mortality, in conjunction with
achieving lower episode spending in all areas. Among
patients who avoided complications or readmissions at
high-value hospitals, lower spending was driven by professional payments, but not index hospitalization, postacute care, or readmission payments. These findings
may reflect a higher proportion of elective operations
performed at high-value centers, with improved postoperative care leading to fewer complications and lower
spending. These data identify specific clinical outcomes
and sources of modifiable payment variation which may
inform approaches to bundled payments and valuebased reimbursement for hospitals and payors.
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